Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Board Changes

25 Sep 2025 07:00

RNS Number : 7148A
Frontier IP Group plc
25 September 2025
 

RNS

AIM: FIPP

25 September 2025

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Announcement of Board Change

 

Frontier IP, a specialist in commercialising intellectual property, today announces that

Matthew White (Chief Commercialisation Officer) has decided to leave the Group to pursue an opportunity as Chief Executive Officer of a Cambridge based early-stage medical devices company.

 

It is currently intended that Mr White will remain with the Company as Chief Commercialisation Officer and an Executive Director of the Company until the end of his six month notice period on 24 March 2026.

 

The Group is in discussions about a successor and a further update will be issued when appropriate.

 

Frontier IP Chief Executive Officer Neil Crabb said: "I am sorry Matt is leaving the Group. His departure is wholly amicable. In the seven years he has been our Chief Commercialisation Officer, he has played an invaluable role in the progress made by Frontier IP and our portfolio companies. I would like to wish him all the best in the exciting role he is to fulfil. I am sure he will be a great success."

 

Frontier IP Chief Commercialisation Officer Matthew White said: "It has been a privilege to be involved in the development of the Frontier IP portfolio over the last seven years. I look forward to the continued success of the portfolio and Frontier IP's growing engagement in the Cambridge deeptech ecosystem."

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / Daniel Dearden-Williams

 

Singer Capital Markets (Broker)

Charles Leigh-Pemberton / James Fischer

 

T: 0203 328 5656

 

 

T: 0207 496 3000

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOALIMPTMTMTBBA
Date   Source Headline
6th Nov 20203:07 pmRNSHolding(s) in Company
5th Nov 20202:34 pmRNSGrant of Options
5th Nov 20207:00 amRNSAnnual results webcast hosted by LSE
5th Nov 20207:00 amRNSFinal Results
26th Oct 20207:00 amRNSPublication of newsletter
15th Oct 20207:00 amRNSTVG collaboration - Pirbright & ECO Animal Health
21st Sep 20207:00 amRNSBonduelle collaboration with Fieldwork Robotics
16th Sep 20207:00 amRNSUK Gov Future Fund invests £360k in Nandi Proteins
14th Sep 20207:00 amRNSInnovate UK backs Fieldwork Robotics with grant
9th Sep 20205:11 pmRNSHolding(s) in Company
7th Sep 20207:00 amRNSSoftware Commercialisation Director appointment
1st Sep 20207:00 amRNSElute Intelligence Patent Reader launched
24th Aug 20205:48 pmRNSHolding(s) in Company
10th Aug 20207:00 amRNSUK Gov Future Fund invests £250,000 in Pulsiv
5th Aug 20206:24 pmRNSHolding(s) in Company
4th Aug 20202:45 pmRNSHolding(s) in Company
31st Jul 20205:00 pmRNSTotal Voting Rights
30th Jul 202011:45 amRNSHolding(s) in Company
29th Jul 20202:46 pmRNSHolding(s) in Company
29th Jul 20209:11 amRNSHolding(s) in Company
28th Jul 20205:22 pmRNSHolding(s) in Company
22nd Jul 202012:50 pmRNSHolding(s) in Company
21st Jul 20209:05 amRNSSecond Price Monitoring Extn
21st Jul 20209:00 amRNSPrice Monitoring Extension
21st Jul 20207:00 amRNSResult of Capital Raising
20th Jul 20204:37 pmRNSPrimaryBid.com Offer
20th Jul 20204:35 pmRNSProposed Capital Raising of a minimum of £2m
20th Jul 20202:00 pmRNSCambridge Raman Imaging completes £250,000 funding
14th Jul 20207:00 amRNSAquaInSilico wins grant to commercialise software
13th Jul 20207:00 amRNSPulsiv demonstrates strong progress
7th Jul 20207:00 amRNSCelerum supports development for PlanSea Solutions
6th Jul 20207:00 amRNSBosch collaboration with Fieldwork
30th Jun 20205:00 pmRNSTotal Voting Rights
23rd Jun 20207:00 amRNSThe Vaccine Group: strong COVID-19 progress
17th Jun 20207:00 amRNSCambridge & FIPP collaborate to tackle gum disease
28th May 20207:10 amRNSPortfolio news: Access to Elute's Patent Reader
28th May 20207:00 amRNSExercise of Options and Total Voting Rights
26th May 20207:00 amRNSPortfolio news – Exscientia raises $60 million
7th May 20207:00 amRNSExscientia and SRI International collaborate
1st May 20207:00 amRNSPortfolio news – Molendotech raises £425,000
15th Apr 20207:00 amRNSPortfolio news – Pulsiv Solar awarded patent
9th Apr 20207:00 amRNSPortfolio news: Alusid launches luxury Block range
6th Apr 202012:01 pmRNSHolding(s) in Company
1st Apr 20207:00 amRNSExscientia announces joint initiative re COVID-19
30th Mar 20204:40 pmRNSSecond Price Monitoring Extn
30th Mar 20204:36 pmRNSPrice Monitoring Extension
30th Mar 20207:00 amRNSElute Intelligence’s AI to back COVID-19 research
26th Mar 20207:00 amRNSPortfolio news: new portfolio company AquaInSilico
25th Mar 20207:00 amRNSUnaudited Half Year Results
19th Mar 20207:00 amRNSFrontier partners University of Lisbon competition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.